- Home
- VIGL vs ESP Comparison
VIGL vs ESP Comparison
Compare VIGL & ESP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ESP
- Stock Information
- Founded
- VIGL 2020
- ESP 1928
- Country
- VIGL United States
- ESP United States
- Employees
- VIGL N/A
- ESP N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ESP Industrial Machinery/Components
- Sector
- VIGL Health Care
- ESP Technology
- Exchange
- VIGL Nasdaq
- ESP Nasdaq
- Market Cap
- VIGL 89.3M
- ESP 84.1M
- IPO Year
- VIGL 2022
- ESP N/A
- Fundamental
- Price
- VIGL $2.80
- ESP $27.96
- Analyst Decision
- VIGL Strong Buy
- ESP
- Analyst Count
- VIGL 5
- ESP 0
- Target Price
- VIGL $21.00
- ESP N/A
- AVG Volume (30 Days)
- VIGL 2.7M
- ESP 14.7K
- Earning Date
- VIGL 03-25-2025
- ESP 02-12-2025
- Dividend Yield
- VIGL N/A
- ESP 3.06%
- EPS Growth
- VIGL N/A
- ESP 31.14
- EPS
- VIGL N/A
- ESP 2.45
- Revenue
- VIGL N/A
- ESP $43,917,522.00
- Revenue This Year
- VIGL N/A
- ESP N/A
- Revenue Next Year
- VIGL N/A
- ESP N/A
- P/E Ratio
- VIGL N/A
- ESP $10.50
- Revenue Growth
- VIGL N/A
- ESP 18.62
- 52 Week Low
- VIGL $1.49
- ESP $20.20
- 52 Week High
- VIGL $6.06
- ESP $33.00
- Technical
- Relative Strength Index (RSI)
- VIGL 71.42
- ESP 49.21
- Support Level
- VIGL $2.54
- ESP $25.40
- Resistance Level
- VIGL $2.88
- ESP $29.30
- Average True Range (ATR)
- VIGL 0.20
- ESP 1.00
- MACD
- VIGL 0.03
- ESP -0.16
- Stochastic Oscillator
- VIGL 89.73
- ESP 65.64
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.